Outside of Europe, the market differences can be even more pronounced. Developing cord blood-derived regulatory T-celll therapeutics for treating autoimmune diseases and inflammatory disorders. Pluripotent stem cells, cancer immunotherapies. Has a Phase II-approved immunotherapy that utilizes autologous dendritic cells loaded with irradiated tumor cells and a preclinical program developing 3D-retinal organoids for vision loss. All figures were provided from Google Finance and are current as of market closure time on March
The company plans for this treatment to be autologous.
Stem Cells & Cellular Therapy Company Career Pages
The company plans for this treatment to be autologous. Stem cell therapies; therapeutic stem cell exosomes. Geron wants to demonstrate its ability to create a safe product that can be produced in large quantities. In addition to these stem cell companies, there are nearly other market competitors. Immunotherapies for cancer and stem cell therapies for degenerative diseases. Cellular immunotherapy products for kidney transplant MDRX. In the table below, companies developing human stem cell therapeutics are included.